Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News F-star Therapeutics Inc. FSTX

Healthcare Biotechnology
F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:FSTX)

invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.

Business Wire March 8, 2023

F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma

GlobeNewswire March 7, 2023

invoX Pharma and F-star Therapeutics issue Joint Statement

GlobeNewswire January 26, 2023

F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress

GlobeNewswire December 6, 2022

F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research

GlobeNewswire November 7, 2022

F-STAR THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX

PR Newswire October 5, 2022

F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

GlobeNewswire August 11, 2022

SHAREHOLDER ALERT: Weiss Law Reminds FSTX, STCN, GRRB, and ZEN Shareholders About Its Ongoing Investigations

PR Newswire July 21, 2022

F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody

GlobeNewswire July 20, 2022
View More News ››

Opinion & Analysis (NDAQ:FSTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:FSTX)

4 BIOTECH STOCKS FOR YOUR INVESTMENT WATCHLIST!

FSTX, RIGL, CRNX, KLDO,  https://www.aviseanalytics.com/4-biotech-stocks-for-your-investment-watchlist/
AviseAnalytics - August 9, 2021

4 BIOTECH STOCKS FOR YOUR INVESTMENT WATCHLIST!

FSTX, RIGL, CRNX, KLDO   [url=https://www.aviseanalytics.com/4-biotech-stocks-for-your-investment-watchlist/]Read More[/url] ...
AviseAnalytics - August 9, 2021
View more Bullboard ››

Lancaster Resources Inc.

Lancaster Resources Inc.

Lancaster Resources Inc. is a Canada-based company engaged in exploring lithium and uranium and other critical minerals. The ...
View More »